Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study.
暂无分享,去创建一个
H. Sather | D. Arthur | F. Uckun | P. Steinherz | M. Trigg | P. Gaynon | G. Reaman | D. Tubergen | H. Sather | P. G. Steinherez | Gregory H. Reaman | Diane C. Arthur | Fatih M. Uckun
[1] G. Reaman,et al. Immunotoxins for treatment of leukemia and lymphoma. , 1995, Leukemia & lymphoma.
[2] R. Larson,et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. , 1995, Blood.
[3] A. Burkhardt,et al. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases , 1995, Science.
[4] C. C. Bailey,et al. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X , 1995, The Lancet.
[5] T. Rabbitts,et al. Chromosomal translocations in human cancer , 1994, Nature.
[6] W. Hiddemann,et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. , 1994, Blood.
[7] R. Gelber,et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] H. Sather,et al. The role of radiation therapy in the treatment of acute lymphoblastic leukemia with lymphomatous presentation: a report from the Childrens Cancer Group. , 1993, International journal of radiation oncology, biology, physics.
[9] G. Reaman,et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] F. Behm,et al. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. , 1993, Blood.
[11] H. Sather,et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] H. Sather,et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] F. Behm,et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy , 1991, The Lancet.
[14] J. Ledbetter,et al. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. , 1990, Blood.
[15] R. Gale,et al. Acute lymphoblastic leukemia: recent advances in biology and therapy. , 1989, Blood.
[16] B. Koller,et al. Biphenotypic leukemic lymphocyte precursors in CD2+CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues. , 1989, Blood.
[17] J. Ledbetter,et al. Immunobiologic differences between normal and leukemic human B-cell precursors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[18] H. Sather,et al. INTENSIVE THERAPY FOR CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKAEMIA AND UNFAVOURABLE PRESENTING FEATURES Early Conclusions of Study CCG-106 by the Childrens Cancer Study Group , 1988, The Lancet.
[19] M. Greaves. Differentiation-linked leukemogenesis in lymphocytes. , 1986, Science.
[20] K. Foon,et al. Immunologic classification of leukemia and lymphoma. , 1986, Blood.
[21] A. Bleyer,et al. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M. Borowitz,et al. Clinicopathologic aspects of E rosette negative T cell acute lymphocytic leukemia: a Pediatric Oncology Group study. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] S. Sallan,et al. Comparative analysis of treatment programs for childhood acute lymphoblastic leukemia. , 1985, Seminars in oncology.
[24] K. Starling,et al. Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study). , 1982, Blood.
[25] J. Peto,et al. Immunologically Defined Subclasses of Acute Lymphoblastic Leukaemia in Children: their Relationship to Presentation Features and Prognosis , 1981, British journal of haematology.
[26] E. Reinherz,et al. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[27] D G Thomas,et al. Trend and homogeneity analyses of proportions and life table data. , 1977, Computers and biomedical research, an international journal.
[28] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[29] L. Borella,et al. Clinical importance of lymphoblasts with T markers in childhood acute leukemia. , 1975, The New England journal of medicine.
[30] N. Breslow,et al. Analysis of Survival Data under the Proportional Hazards Model , 1975 .
[31] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[32] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[33] C. Pui,et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] L. Frankel,et al. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group. , 1992, Leukemia.
[35] Jonathan J. Shuster,et al. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study , 1990 .
[36] F. Behm,et al. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. , 1990, Blood.
[37] F. Uckun,et al. Immunophenotype-karyotype associations in human acute lymphoblastic leukemia. , 1989, Blood.
[38] H. Sather,et al. Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P. , 1988, The American journal of pediatric hematology/oncology.
[39] A. Ganser,et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults , 1988 .
[40] D. Cox. Regression Models and Life-Tables , 1972 .